# OnCo record bevacizumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/bevacizumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "bevacizumab" ;
  schema:name "Bevacizumab"@en ;
  schema:description "Bevacizumab is a humanised antibody that soaks up VEGF-A, the signal tumours use to grow new blood vessels. Approved in 2004, it partners chemotherapy in colorectal, ovarian, cervical, lung, kidney and liver cancer and glioblastoma, and adds to trifluridine/tipiracil in late-line bowel cancer; hypertension, protein in the urine and bleeding are its characteristic side effects."@en ;
  schema:url <https://onco.cc/drugs/bevacizumab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Bevacizumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q413299> ;
  schema:citation <https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125085s340lbl.pdf>, <https://www.nice.org.uk/guidance/ta1136>, <https://www.nice.org.uk/guidance/ta212>, <https://www.ema.europa.eu/en/medicines/human/EPAR/avastin> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-VEGF)" ;
  schema:alternateName "Avastin (and biosimilars)" ;
  onco:approval "US 2004: First-line metastatic colorectal cancer with 5-FU chemotherapy", "US 2006: NSCLC; later ovarian, cervical, RCC, glioblastoma, HCC", "US 2023: Refractory mCRC with trifluridine/tipiracil (SUNLIGHT)", "US 2014: Platinum-resistant ovarian cancer with chemotherapy; recurrent/metastatic cervical cancer with chemotherapy", "US 2018: First-line stage III-IV ovarian cancer after surgery", "US 2020: First-line maintenance with olaparib in HRD-positive ovarian cancer", "EU 2005: Metastatic colorectal cancer with fluoropyrimidine-based chemotherapy", "England (NICE) 2026: First- and second-line metastatic colorectal cancer with fluoropyrimidine-based chemotherapy, only when targeted treatment or immunotherapy is unsuitable" ;
  onco:acceleratedApproval "US 2008-02-22: In combination with paclitaxel for patients who have not received chemotherapy for metastatic HER2 negative breast cancer", "US 2009-05-05: Progressive glioblastoma following prior therapy" ;
  onco:acceleratedApprovalConfirmed "US 2017-12-05: Progressive glioblastoma following prior therapy" ;
  onco:related <https://onco.cc/drugs/bevacizumab-glioma/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/glioblastoma/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/angiogenesis-models/> ;
  onco:targets <https://onco.cc/targets/vegf/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/hetero/> ;
  onco:pathways <https://onco.cc/pathways/vegf-angiogenesis/> ;
  onco:trials <https://onco.cc/trials/sunlight/>, <https://onco.cc/trials/paradigm/>, <https://onco.cc/trials/nct04854668/>, <https://onco.cc/trials/nct05445778/>, <https://onco.cc/trials/nct07221357/>, <https://onco.cc/trials/nct07775287/>, <https://onco.cc/trials/nct07216703/>, <https://onco.cc/trials/nct07318558/>, <https://onco.cc/trials/nct06824467/>, <https://onco.cc/trials/nct03390686/>, <https://onco.cc/trials/nct05654454/>, <https://onco.cc/trials/nct06921785/>, <https://onco.cc/trials/nct04547166/>, <https://onco.cc/trials/nct06819007/>, <https://onco.cc/trials/nct03847428/>, <https://onco.cc/trials/nct06123884/>, <https://onco.cc/trials/nct07722494/>, <https://onco.cc/trials/nct06497985/>, <https://onco.cc/trials/nct05904886/>, <https://onco.cc/trials/nct07225270/>, <https://onco.cc/trials/nct07564141/>, <https://onco.cc/trials/nct04712643/>, <https://onco.cc/trials/nct07676162/>, <https://onco.cc/trials/nct07527858/>, <https://onco.cc/trials/nct06445062/>, <https://onco.cc/trials/nct05775159/>, <https://onco.cc/trials/nct06512051/>, <https://onco.cc/trials/nct07024784/>, <https://onco.cc/trials/nct07446322/>, <https://onco.cc/trials/nct06107413/>, <https://onco.cc/trials/nct07054567/>, <https://onco.cc/trials/nct06792695/>, <https://onco.cc/trials/nct07805551/>, <https://onco.cc/trials/nct07479485/>, <https://onco.cc/trials/nct07079631/>, <https://onco.cc/trials/nct06820463/>, <https://onco.cc/trials/nct06948448/>, <https://onco.cc/trials/nct06679985/>, <https://onco.cc/trials/nct06873763/>, <https://onco.cc/trials/nct07071714/>, <https://onco.cc/trials/nct04068610/>, <https://onco.cc/trials/nct05739981/>, <https://onco.cc/trials/nct05919264/>, <https://onco.cc/trials/nct05797168/>, <https://onco.cc/trials/nct07714668/>, <https://onco.cc/trials/nct05440708/>, <https://onco.cc/trials/nct07042802/>, <https://onco.cc/trials/nct07244705/>, <https://onco.cc/trials/nct04938583/>, <https://onco.cc/trials/nct06427941/>, <https://onco.cc/trials/nct06096779/>, <https://onco.cc/trials/nct07474727/>, <https://onco.cc/trials/nct06607458/>, <https://onco.cc/trials/nct06890338/>, <https://onco.cc/trials/nct06840002/>, <https://onco.cc/trials/nct06859775/>, <https://onco.cc/trials/nct05733598/>, <https://onco.cc/trials/nct06843447/>, <https://onco.cc/trials/nct06040099/>, <https://onco.cc/trials/nct06493760/>, <https://onco.cc/trials/nct05824975/>, <https://onco.cc/trials/nct06558227/>, <https://onco.cc/trials/nct05489211/>, <https://onco.cc/trials/nct04931342/>, <https://onco.cc/trials/nct02519348/>, <https://onco.cc/trials/nct04524871/>, <https://onco.cc/trials/nct07059845/>, <https://onco.cc/trials/nct06496971/>, <https://onco.cc/trials/nct06465563/>, <https://onco.cc/trials/nct03899155/>, <https://onco.cc/trials/nct06276283/>, <https://onco.cc/trials/nct06061809/>, <https://onco.cc/trials/nct05405595/>, <https://onco.cc/trials/nct06783647/>, <https://onco.cc/trials/nct06951503/>, <https://onco.cc/trials/nct06771622/>, <https://onco.cc/trials/nct04262466/>, <https://onco.cc/trials/nct06895928/>, <https://onco.cc/trials/nct06730750/>, <https://onco.cc/trials/nct03148418/>, <https://onco.cc/trials/nct05867420/>, <https://onco.cc/trials/nct04121455/>, <https://onco.cc/trials/nct07297212/>, <https://onco.cc/trials/nct02671435/>, <https://onco.cc/trials/nct05584670/>, <https://onco.cc/trials/nct05112965/>, <https://onco.cc/trials/nct02734004/>, <https://onco.cc/trials/nct07448922/>, <https://onco.cc/trials/nct05101070/>, <https://onco.cc/trials/nct06750094/>, <https://onco.cc/trials/nct06906341/>, <https://onco.cc/trials/nct07111546/>, <https://onco.cc/trials/nct06271837/>, <https://onco.cc/trials/nct06016062/>, <https://onco.cc/trials/mountaineer/>, <https://onco.cc/trials/nct06697197/>, <https://onco.cc/trials/nct07283367/>, <https://onco.cc/trials/nct04626635/>, <https://onco.cc/trials/nct05239741/>, <https://onco.cc/trials/nct06703177/>, <https://onco.cc/trials/nct07286266/>, <https://onco.cc/trials/nct06796907/>, <https://onco.cc/trials/gog-0218-icon7/>, <https://onco.cc/trials/paola-1/>, <https://onco.cc/trials/keynote-b96/>, <https://onco.cc/trials/avf2107g/>, <https://onco.cc/trials/cairo3/>, <https://onco.cc/trials/cairo5/>, <https://onco.cc/trials/tribe/>, <https://onco.cc/trials/tribe2/> ;
  onco:people <https://onco.cc/people/judah-folkman/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-hurwitz-bevacizumab-crc-nejm-2004/> .